Specifics on Active & Closed Studies

An Efficacy and Safety Trial of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment (aMCI) due to Alzheimer's Disease (Prodromal AD)

Study Status: 
Closed
Study Description: 

What is the purpose of this research study?

The purpose of this clinical trial is to evaluate the efficacy, safety and tolerability of MK-8931, a drug that may have the potential to treat Alzheimer's disease (AD). MK-8931 reduces levels of "A-beta" (a small piece of protein). A-beta may be involved in causing Alzheimer's disease.

For more details of the study, please see the attached document.

Study Coordinator(s): 

Sehily JaimesTel:  617-643-5200

Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) versus Placebo

Study Status: 
Closed
Study Description: 

The purpose of this study is to find out if a new drug called Solanezumab can help people with Alzheimer's disease (AD). We also want to find out if Solanezumab is safe to take without causing too many side effects. In AD, amyloid fragments gather and form hard plaques. Doctors think that amyloid can cause symptoms such as memory loss and confusion. We hope that Solanezumab can reduce the amount of amyloid in the brain.

 

Who is eligible?

Please see attached.

Study Coordinator(s): 

Sehily Jaimes

Tel:  617-643-5200

Therapeutic Effects of Intranasally-Administered Insulin in Adults with Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD) (ADC-046-INI)

Study Status: 
Closed
Study Description: 

The purpose of this study is to find out if a type of insulin (Humulin® R) improves memory when it is given intranasally (as a "nasal spray") to adults with a mild cognitive (memory) impairment or early Alzheimer's disease (AD). This study will also look at the effect of intranasal insulin (INI) has on the brain structure and function and markers of AD in the cerebrospinal fluid (CSF) and blood.

 

More information is attached.

 

Study Coordinator(s): 

Sehily Jaimes

Tel:  617-643-5200

A Randomized, 18-Week, Placebo-Controlled, Double-Blind, Parallel-Group Study of the Safety and Efficacy of PF-05212377 (SAM-760) in Subjects with Mild to Moderate AD with Existing Neuropsychiatric Symptoms on a Stable Daily Dose of Donepezil

Study Status: 
Closed
Study Description: 

The purpose of this clinical trial is to evaluate the safety of PF-05212377 (SAM-760) and the effect of PF-05212377 (SAM-760) on cognition and some behavioral symptoms associated with Alzheimer's disease.

 

We are looking for participants who:

 

-- have a diagnosis of Alzheimer's disease

-- are age 60 or older

-- have a reliable caregiver or family member who is able to accompany them to study visits

-- are in stable medical condition

-- are on stable doses of Aricept (donepezil)

-- are not on any other medications for Alzheimer's disease (antidepressants are allowed)

 

More information is attached.

Study Coordinator(s): 

Sehily Jaimes

Tel:  617-643-5200

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects with Mild Alzheimer's Disease

Study Status: 
Closed
Study Description: 

What is the purpose of this study?

The purpose of this clinical trial is to evaluate the efficacy, safety and tolerability of BMS241027, a drug that may have the potential to treat Alzheimer's disease (AD). In AD, there are abnormally-high levels of a protein, called tau, in the fluid surrounding the brain. We hope that BMS241027 can decrease the levels of tau.

 

Who is eligible?

We are looking for participants who:

-- have been diagnosed with mild Alzheimer's disease

-- are between the age of 50 and 90

-- have a reliable caregiver or family member who is able to accompany them to study visits

-- are in stable medical condition

-- are willing to undergo MRI and lumbar punctures

 

People taking approved Alzheimer's medications (donepezil/Aricept, galantamine/Razadyne, rivastigmine/Exelon, memantine/Namenda) are eligible to take part in this study and can continue taking these medications during the study.

 

Please see the attached study description for more information.

Study Coordinator(s): 

Sehily Jaimes

Tel:  617-643-5200

The Risk Evaluation and Education for Alzheimer's Disease (REVEAL) Study

Study Status: 
Closed
Study Description: 

WHAT IS THE REVEAL STUDY?

Many people with mild memory concerns wonder whether they will develop Alzheimer's disease (AD).

The REVEAL study is a multi-center, NIH-funded research project based at Brigham and Women's Hospital.

The goal of REVEAL is to use genetic information to help predict whether someone with mild memory problems will develop AD.

 

WHO IS ELIGIBLE TO PARTICIPATE?

You may participate if you:

* Are at least 55 years old

* Speak and read English

* Have been given a diagnosis of Mild Cognitive Impairment (MCI)

* Have a close friend or family member to be a study partner

 

More information is attached.

Study Coordinator(s): 

Sehily JaimesTel:  617-643-5200

Neural Correlates of Olfactory Function in Neurodegenerative Disease

Study Status: 
Closed
Study Description: 

We are seeking healthy adults, aged 18 or older, to participate in a research study. The goal of the study is to examine olfactory function (or the sense of smell) in healthy individuals and in individuals with asymptomatic prodromal Alzheimer's disease, clinical Alzheimer's disease, Mild Cognitive Impairment, Dementia with Lewy Bodies, and Frontotemporal Dementia.

 

If you qualify, you will be asked to take a test that measures your ability to identify a group of everyday odors. You will also be asked to undergo an MRI brain scan. While we take pictures of your brain, we will present you with odors and ask you to let you know when you can smell them.

Study Coordinator(s): 

Sehily Jaimes

Tel:  617-643-5200

A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001) in Patients with Mild to Moderate Alzheimer's Disease

Study Status: 
Closed
Study Description: 

The purpose of this clinical trial is to evaluate the efficacy and safety of Bapineuzumab, a drug that has the potential to treat Alzheimer's disease. Bapineuzumab is a vaccine against amyloid (the protein deposits in the brain that are believed to cause Alzheimer's disease). It is hoped that Bapineuzumab will attach to the amyloid protein in the brain and help the body to remove it and in doing so help stop the progression of Alzheimer's disease.

 

WHO IS ELIGIBLE?

We are looking for participants who:

--have been diagnosed with mild-moderate Alzheimer's disease

--are between the age of 50 and 88

--have a reliable caregiver or family member who is able to accompany them to study visits

--are in stable medical condition

--are willing to undergo genetic testing

--are willing to undergo MRI scans

 

People taking approved Alzheimer's medications (donepezil/Aricept, galantamine/Razadyne, rivastigmine/Exelon, memantine/Namenda) are eligible to participate in this study and can continue taking these medications during the study.

 

More information is attached.

Study Coordinator(s): 

Caroline A. Sullivan, BA

Tel:  617-643-5200

Olfactory Deficits in Neurological Disease

Study Status: 
Active
Study Description: 

We are seeking healthy adults, aged 18 or older, to participate in a research study. The goal of the study is to examine olfactory function (or the sense of smell) in healthy individuals and in preclinical and clinical subjects with Alzheimer's Disease, Dementia with Lewy Bodies, or Frontotemporal Dementias.

 

If you qualify, you will be asked to undergo tests that measure your ability to discriminate, identify, remember, and evaluate a group of everyday odors. The study will take place at the Departments of Neurology or Psychiatry of the Massachusetts General Hospital (either on the Charlestown Navy Yard or the main campus of the hospital). It will take approximately one hour to complete the tests.

 

You will be asked to do this once a year. You will not be paid for participating in the study.

Study Coordinator(s): 

Sehily Jaimes

Tel:  617-643-5200

A Phase 2, Multi-Center, 24-Month, Randomized, Third-Party Unblinded, Placebo-Controlled, Parallel-Group Amyloid Imaging Positron Emission Tomography (PET) and Safety Trial of ACC-001 and QS-21 Adjuvant in Subjects with Early Alzheimer's Disease

Study Status: 
Closed
Study Description: 

WHAT IS THE PURPOSE OF THIS STUDY?

The purpose of this clinical trial is to evaluate the efficacy, safety and tolerability of ACC-001, a drug that has the potential to treat early Alzheimer's disease. ACC-001 is a vaccine against amyloid. In a healthy brain, amyloid is broken down and eliminated. In early Alzheimer's disease, amyloid fragments gather and from hard plaques. Doctors think that the amyloid plaques cause symptoms like memory loss and confusion.

QS-21 is an adjuvant. An adjuvant is a substance that helps to stimulate the body's immune system to produce antibodies. Antibodies are a type of protein made by white blood cells to destroy foreign substances in the body. It is hope that ACC-001 alone or when mixed with QS-21 will act a vaccine to help the body make antibodes to destroy the amyloid protein in the brain.

 

WHO IS ELIGIBLE?

We are looking for participants who:

* have early onset Alzheimer's disease or have changes in memory also known as Mild Cognitive Impairment (MCI)

* are between the age of 50 and 80

* have a reliable caregiver or family member who is able to accompany them to study visits

* are in stable medical condition

* are willing to undergo a lumbar puncture (spinal tap)

 

People taking approved Alzheimer's medications (donepezil/Aricept, galantamine/Razadyne, rivastigmine/Exelon, memantine/Namenda) are eligible to take part in this study and can continue taking these medications during the study. You do not have to be on these medications to take part in the study.

 

More information is attached.

Study Coordinator(s): 

Caroline A. Sullivan, BA

Tel:  617-643-5200

Syndicate content